Company Tagline
Open cells to new possibilities: Accelerating cell therapy processes from discovery through manufacturing with Flowfect®
Industry Category
Business Keywords
Company Description
Kytopen is at the forefront of biotechnology research, dedicated to developing and commercializing pioneering genome engineering platforms. These platforms are designed to accelerate the discovery, development, and manufacturing of gene-modified cell therapies. Kytopen's innovative Flowfect® platform, born from research at MIT, seamlessly integrates microfluidics and automation to transform the delivery of genome engineering materials to therapeutically relevant cells. This approach is exceptionally fast, scalable, and economically efficient, surpassing traditional methods.
In a significant move, Kytopen launched the Flowfect Discover™ in May 2023, an automated high-throughput genome engineering platform. This launch was accompanied by the announcement of strategic partnerships with leading Contract Development and Manufacturing Organizations (CDMOs) and translational academic medical centers. Kytopen is committed to addressing manufacturing challenges early in the discovery phase by leveraging Flowfect Discover™ alongside the Flowfect Tx™ large-scale delivery device in process development workflows, thus enabling faster and more cost-effective innovation.
Located at 750 Main St, Cambridge, Massachusetts 02139, US, Kytopen is driving advancements in cell therapy and genetic engineering. The company is poised for continued growth and innovation in the biotechnology sector. We invite the management at Kytopen to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and impact.
Kytopen est à l'avant-garde de la recherche biotechnologique, se consacrant au développement et à la commercialisation de plateformes d'ingénierie génomique novatrices. Ces plateformes sont conçues pour accélérer la découverte, le développement et la fabrication de thérapies cellulaires génétiquement modifiées. La plateforme innovante Flowfect® de Kytopen, issue de la recherche au MIT, intègre de manière transparente la microfluidique et l'automatisation pour transformer la livraison de matériaux d'ingénierie génomique aux cellules thérapeutiquement pertinentes. Cette approche est exceptionnellement rapide, évolutive et économiquement efficace, surpassant les méthodes traditionnelles.
Dans une démarche significative, Kytopen a lancé Flowfect Discover™ en mai 2023, une plateforme automatisée à haut débit d'ingénierie génomique. Ce lancement a été accompagné de l'annonce de partenariats stratégiques avec des organisations de pointe de développement et de fabrication sous contrat (CDMO) et des centres médicaux universitaires translationnels. Kytopen s'engage à relever les défis de fabrication dès la phase de découverte en tirant parti de Flowfect Discover™ aux côtés du dispositif de livraison à grande échelle Flowfect Tx™ dans les flux de travail de développement de processus, permettant ainsi une innovation plus rapide et plus rentable.
Située au 750 Main St, Cambridge, Massachusetts 02139, États-Unis, Kytopen stimule les avancées dans la thérapie cellulaire et l'ingénierie génétique. L'entreprise est prête pour une croissance et une innovation continues dans le secteur de la biotechnologie. Nous invitons la direction de Kytopen à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme afin d'amplifier davantage leur portée et leur impact.
Key Personnel / Employees
Compare Companies Side by Side
Compare Kytopen with 3 companies in Biotechnology-Research
| Comparison Field |
KytopenMain Company |
CRISPR Medicine NewsView Profile |
MaxCyte, Inc.View Profile |
Poseida Therapeutics...View Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2019 | 1999 | 2014 |
|
Company Size
|
— | 2-10 | 51-200 | 201-500 |
|
City
|
Cambridge, Massachusetts | Rockville, Maryland | San Diego, California | |
|
Country
|
United States | United States | United States | |
|
Skills & Keywords
Comparing with main company
|
28 Total Skills
Genome Engineering
Cell Therapy
Microfluidics
Automation
Gene-Modified Cell Therapies
Biotechnology
Flowfect Platform
CD34+ stem cells
CRISPR
Stem Cells
Gene Editing
NK cells
Drug Discovery
Transfection
Gene Therapy
Immunology
CAR T-cell
Cas9
Genetic engineering
T cells
Mechanical engineering
Manufacturing
Cell engineering
Immunotherapy
Mammalian cells
mRNA
RNP delivery
Nonviral
|
6 Total
6 Unique
Unique Skills:
clinical trials
Genetic medicine
Interviews
Media
Medicine
News
|
16 Total
1 Common
15 Unique
Match
4%
Common Skills:
Biotechnology
Unique Skills:
Bispecifics
Cancer
Cancer Research
CARMA
Cell Engineering
Electroporation
+9
|
19 Total
2 Common
17 Unique
Match
7%
Common Skills:
Biotechnology
Genome Engineering
Unique Skills:
Adoptive Cell Therapy
Allogeneic
CAR-T cells
Cas-CLOVER™
Cytotoxic T Lymphocytes
Immuno-oncology
+11
|
4
Total Companies1999
Oldest Founded1
Countries65
Unique SkillsSimilar Companies
Other organizations in the same industry
Human BioSciences, Inc. USA
Biotechnology-ResearchProducing biotechnology advancements in Kollagen™ wound products for safe, simple, effective use in...
Caladrix
Biotechnology-ResearchFighting Alzheimer’s by Restoring the Brain’s Innate Clearance Systems
COGNANO, Inc.
Biotechnology-ResearchCOGNANO, Inc. is a venture to aim for computer-supported drug discovery.
ITQB NOVA Innovation Office
Biotechnology-ResearchITQB at the forefront of innovation in Portugal
Alternative Company Names
This company is also known as